NCT01016600View on ClinicalTrials.gov

Azacitidine and Lenalidomide for Acute Myeloid Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

November 30, 2013

Study Completion Date

October 31, 2014

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

Lenalidomide

DRUG

Azacitidine

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT01016600 - Azacitidine and Lenalidomide for Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter